Business Context and Reporting Period
Company: Oncolytics Biotech Inc.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: April 2017 (Specifically April 5, 2017)
Headquarters: Calgary, Alberta, Canada
This filing serves to distribute a press release dated April 5, 2017, regarding clinical trial results for the company's product candidate, REOLYSIN.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory submission of a news release and does not contain financial statements or quantitative financial data.
Material Changes
The material event reported is a clinical data announcement rather than a financial change. The filing highlights that REOLYSIN demonstrated the ability to more than double overall survival in patients with mutated p53 metastatic breast cancer.
Guidance, Outlook, and Management Commentary
- Clinical Outcome: The press release (Exhibit 99.1) states that REOLYSIN more than doubled overall survival in the specified patient population (mutated p53 metastatic breast cancer).
- Management Commentary: No specific forward-looking financial guidance or management commentary regarding future operations is included in the text of this Form 6-K.
- Risks and Contingencies: No specific risks or contingencies are detailed in this filing text.
Important Facts for Investor Verification
- Verify the full text of the April 5, 2017 press release (Exhibit 99.1) for detailed statistical data regarding the "more than doubled" survival claim.
- Confirm the specific patient cohort size and study design parameters for the mutated p53 metastatic breast cancer trial.
- Review subsequent filings for any regulatory decisions or clinical trial updates resulting from this data.
- Note that this filing contains no financial performance data; investors should refer to the most recent Form 20-F or quarterly reports for financial status.